Cidara Therapeutics (CDTX) Tops Q3 EPS by 6c

Cidara Therapeutics (NASDAQ: CDTX) reported Q3 EPS of ($0.09), $0.06 better than the analyst estimate of ($0.15). Revenue for the quarter came in at $12.72 million versus the consensus estimate of $8.14 million.

For earnings history and earnings-related data on Cidara Therapeutics (CDTX) click here.

You May Also Be Interested In

• Etsy upgraded to buy at BofA on durable growth, buyback potential
• Citi cuts Weibo stock rating to Neutral, lowers price target
• Ross Stores raises 2026 outlook after strong second-quarter results